Immune checkpoint inhibitors

About this approach

Immune checkpoint inhibitors are medicines that release certain brakes on immune cells, helping the immune system recognize and attack cancer. They include drugs directed at pathways such as PD-1, PD-L1 and CTLA-4. These medicines have established uses in several cancers, but suitability depends on the diagnosis, stage, previous treatment and sometimes biomarker results. They are one part of immunotherapy, with a different mechanism and evidence base from vaccines, CAR T cells or nonspecific immune-support products.

Where it fits: Established immunotherapy for selected cancer settings

Where this treatment is used

Checkpoint inhibitors may be used alone, together or with chemotherapy and other treatments in particular cancer settings. Some patients have long-lasting benefit, while others do not respond or develop resistance. Tests such as PD-L1 expression or mismatch-repair assessment can inform certain decisions, but a test result does not guarantee an individual outcome. The evidence for one drug combination cannot simply be transferred to another cancer or treatment stage. These medicines can also activate immune responses against normal tissues, which shapes eligibility and monitoring. Response assessment may require careful interpretation of symptoms, examination findings and scans over time.

Procedure and practical considerations

Immune-related inflammation can affect the bowel, lungs, liver, kidneys, hormone-producing glands and other organs. New diarrhea, breathlessness, severe fatigue or other changes should be reported promptly using the team’s instructions. Reactions can occur during treatment or after it has ended, and some need urgent assessment or ongoing hormone replacement. Management may involve pausing treatment and medicines that suppress inflammation.

Cancer guides that discuss this treatment

These cancer-type guides include this treatment among their connected approaches. Open a guide to see the related terminology, treatments, and clinic profiles.

Clinics reporting this approach

These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.